WILLIAM J. PETERS - 06 Mar 2024 Form 4 Insider Report for Amphastar Pharmaceuticals, Inc. (AMPH)

Role
CFO, EVP & TREASURER, Director
Signature
/s/ William J. Peters
Issuer symbol
AMPH
Transactions as of
06 Mar 2024
Transactions value $
-$844,303
Form type
4
Filing time
08 Mar 2024, 16:52:41 UTC
Previous filing
06 Mar 2024
Next filing
19 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMPH Common Stock Options Exercise $99,998 +8,826 +7.31% $11.33 129,626 06 Mar 2024 Direct
transaction AMPH Common Stock Sale -$620,539 -13,404 -10.34% $46.3 116,222 06 Mar 2024 Direct F1, F2
transaction AMPH Common Stock Sale -$219,895 -4,681 -4.03% $46.98 111,541 06 Mar 2024 Direct F1, F3
transaction AMPH Common Stock Sale -$2,448 -51 -0.05% $48 111,490 06 Mar 2024 Direct F1
transaction AMPH Common Stock Tax liability -$101,418 -2,190 -1.96% $46.31 109,300 06 Mar 2024 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMPH Employee Stock Option (right to buy) Options Exercise $0 -8,826 -100% $0* 0 06 Mar 2024 Common Stock 8,826 $11.33 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 5, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.79 to $46.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.795 to $47.47, inclusive.
F4 The reported shares were withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units, or RSUs.
F5 Shares subject to the option are fully vested and immediately exercisable.